The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...

Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, ...